{"id":"br1019b","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Without access to detailed clinical trial data or company disclosures, the precise molecular target and mechanism cannot be reliably determined. BR1019B remains an early-to-mid stage investigational drug with limited public information available regarding its pharmacological action.","oneSentence":"BR1019B is an investigational therapeutic in phase 3 development by Boryung Pharmaceutical, but its specific mechanism of action is not publicly disclosed.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:42:15.113Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06220773","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2024-05-21","conditions":"Essential Hypertension, Type 2 Diabetes Mellitus","enrollment":276}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BR1019B","genericName":"BR1019B","companyName":"Boryung Pharmaceutical Co., Ltd","companyId":"boryung-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}